Abbott, Astrazeneca Signs Agreement To Co-promote Trilipix
AstraZeneca to obtain non-exclusive right to co-promote Trilipix
Abbott and AstraZeneca have announced that they have entered into an agreement for AstraZeneca to co-promote Abbott's Trilipix (fenofibric acid). Its a medication to be used alone or in combination with a statin to treat certain lipid disorders.
Under this agreement, AstraZeneca will obtain the non-exclusive right to co-promote Trilipix alongside Abbott in the US, excluding Puerto Rico.
Jim Helm, Vice President, cardiovascular at AstraZeneca, said: “This agreement allows us to further strengthen our presence with physicians by including Trilipix as an offering to physicians for patients with dyslipidemia.
Trilipix is also used along with diet to lower triglycerides and increase HDL cholesterol in people who are at high risk of heart disease, and are taking a statin medicine to control their LDL cholesterol.
Related Insight
Suppliers Directory
CAMAG - Thin-Layer Chromatography
CAMAG are the Swiss experts on instrumental thin-layer chromatography (TLC).
Suppliers
Durbin - Comparator and Ancillary Supply for Clinical Trials
Durbin combines its heritage of over 45 years of sourcing and distributing specialist pharmaceuticals around the world with a commitment to partnership, working to bring a real difference to the provision of clinical trial comparators and ancillaries.
Suppliers
Scandinavian Packaging - Total Supplier of Plastic Packaging
Scandinavian Packaging has been producing plastic lids and caps specifically for the pharmaceutical and food industry for many years. Scandinavian Packaging is the oldest and one of the largest Scandinavian producers of plastic caps. The company was founded in 1949 and is today is a modern, driven producer of innovative quality plastic caps for the pharmaceutical industry.
Suppliers
ASEBIO - Spanish Bioindustry Association
As the Spanish Bioindustry Association, ASEBIO brings together companies, associations, foundations, universities, technology and research centres that undertake their activities either directly or indirectly related to biotechnology in Spain.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Change of Ownership Applications
Published by Pharmalink Consulting
White Papers
Ellab Temperature Indicator
Published by Ellab
White Papers
Product Brochure
Published by Farfield Group
White Papers
Molecular Imaging
Published by CoreLab Partners
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.